Stereotactic ablative radiotherapy in the UK: Current status and developments

British Journal of Radiology

Volumn 86, Issue 1029, 2013, Pages

  Jain, P ^a   Baker, A ^a   Distefano, G ^b   Scott, A J D ^a   Webster, G J ^c   Hatton, M Q ^d  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; HEALTH SERVICE; HEALTH SURVEY; HUMAN; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY CONTROL; QUESTIONNAIRE; RADIOTHERAPY; REVIEW; STEREOTACTIC ABLATIVE RADIOTHERAPY; STEREOTACTIC TREATMENT; UNITED KINGDOM; EDUCATION; HEALTH CARE QUALITY; LUNG TUMOR; PERSONNEL MANAGEMENT; RADIOSURGERY; RETROSPECTIVE STUDY;

GREAT BRITAIN; HUMANS; LUNG NEOPLASMS; PATIENT SELECTION; QUALITY ASSURANCE, HEALTH CARE; RADIOSURGERY; RETROSPECTIVE STUDIES; STAFF DEVELOPMENT;

EID: 84883028739     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20130331     Document Type: Review

References (31)

1. Hadziahmetovic M, Loo BW, Timmerman RD, Mayr NA, Wang JZ, Huang Z, et al. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer-updates of radiobiology, techniques, and clinical outcomes. Discov Med 2010;9:411-17.
2. Martin A, Gaya A. Stereotactic body radiotherapy: a review. Clin Oncol 2010;22: 157-72. doi: 10.1016/j.clon.2009.12.003
3. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I non-small cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101: 162331. doi: 10.1002/cncr.20539 (Pubitemid 39318910)
4. Lax I, Panettieri V, Wennberg B, Amor Duch M, Naslund I, Baumann P, et al. Dose distributions in SBRT of lung tumors: comparison between two different treatment planning algorithms and Monte- Carlo simulation including breathing motions. Acta Oncol 2006;45:978-88. (Pubitemid 44423149)
5. Timmerman R, Heinzerling J, Abdulrahamn R, Choy H, Meyer JL. Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy. Front Radiat Ther Oncol 2011; 43:395-411. doi: 10.1159/000322503
6. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of riskadapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70:685-92. doi: 10.1016/j.ijrobp.2007.10.053
7. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427. doi: 10.1016/j.ijrobp.2005.05. 034 (Pubitemid 41628038)
8. Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I nonsmall cell lung cancer. Chest 2003:124:1946.
9. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I nonsmall cell lung cancer. Oncologist 2008;13: 309-19. doi: 10.1634/theoncologist.2007-0195 (Pubitemid 351679907)
10. Nagata Y, Wulf J, Lax I, Timmerman R, Zimmermann F, Stojkovski I, et al. Stereotactic radiotherapy of primary lung cancer and other targets: results of consultant meeting of the International Atomic Energy Agency. Int J Radiat Oncol Biol Phys 2011;79: 660-9. doi: 10.1016/j.ijrobp.2010.10.004
11. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010;28:5153-9. doi: 10.1200/JCO.2010.30.0731
12. Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833. doi: 10.1200/JCO.2006.07.5937 (Pubitemid 46630909)
13. National Radiotherapy Implementation Group. Stereotactic body radiotherapy: guidance for clinicians, providers and commissioners. London, UK: NRIG; 2010.
14. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010;37: 4078-101.
15. Duane S, Palmans H, Sharpe P, Vynckier S. Traceability and absorbed dose standards for small fields, IMRT and helical tomotherapy. Workshop on "Absorbed dose and air kerma primary standards"; 9-11 May 2007; Paris, France. Paris, France: NPL; 2007. Available from: http://www.nucleide.org/ ADAKPS-WS/Session%20G%20-%20Special%20Standards/G1-Or-Duane.pdf
16. The Royal College of Radiologists, Institute of Physics and Engineering in Medicine, Society and College of Radiographers. On target: ensuring geometric accuracy in radiotherapy. London, UK: The Royal College of Radiologists; 2008. Available from: http://www.rcr.ac.uk/docs/oncology/pdf/BFCO(08)5-On-target.pdf
17. Baker A, Appleton L, Scott A, Jain P. Current and future impact of stereotactic body radiotherapy on UK oncology services. Imaging Oncol 2011;14-22.
18. Josipovic M, Persson GF, Logadottir A, Smulders B, Westmann G, Bangsgaard JP. Translational and rotational intra- and interfractional errors in patient and target position during a short course of frameless stereotactic body radiotherapy. Acta Oncol 2012;51:610-17. doi: 10.3109/0284186X.2011.626448
19. Li W, Purdie TG, Taremi M, Fung S, Brade A, Cho BC, et al. Effect of immobilization and performance status on intrafraction motion for stereotactic lung radiotherapy: analysis of 133 patients. Int J Radiat Oncol Biol Phys 2011;81:1568-75. doi: 10.1016/j.ijrobp. 2010.09.035
20. Fakir H, Gaede S, Mulligan M, Chen JZ. Development of a novel ArcCHECK(™) insert for routine quality assurance of VMAT delivery including dose calculation with inhomogeneities. Med Phys 2012;39:4203-8. doi: 10.1118/1.4728222
21. Ong C, Verbakel WF, Cuijpers JP, Slotman BJ, Senan S. Dosimetric impact of interplay effect on RapidArc lung stereotactic treatment delivery. Int J Radiat Oncol Biol Phys 2011;79:305-11. doi: 10.1016/j.ijrobp. 2010.02.059
22. Rao M, Wu J, Cao D, Wong T, Mehta V, Shepard D, et al. Dosimetric impact of breathing motion in lung stereotactic body radiotherapy treatment using imagemodulated radiotherapy and volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2012;83:e251-6. doi: 10.1016/j.ijrobp.2011.12.001
23. Nagata Y, Hiraoka M, Mizowaki T, Narita Y, Matsuo Y, Norihisa Y, et al. Survey of stereotactic body radiation therapy in Japan by the Japan 3-d Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 2009;75:343-47. doi: 10.1016/j.ijrobp.2009.02.087
24. Pan H, Simpson DR, Mell LK, Mundt AJ, Lawson JD. A Survey of stereotactic radiation therapy in the United States. Cancer 2011;117: 4566-72. doi: 10.1002/cncr.26067
25. Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA, et al. American Society for Therapeutic Radiology and Oncology; American College of Radiology. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010;76:326-32.
26. Mayles WPM. Survey of the availability and use of advanced radiotherapy technology in the UK. Clin Oncol (R Coll Radiol) 2010;22:636-42. doi: 10.1016/j. clon.2010.06.014
27. rtog.org [homepage on the internet]. Philadelphia, PA: Radiation Therapy Oncology Group; c2010 [cited 25 March 2013]. Available from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails. aspx?study50915.
28. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R. Systemic review of the patterns of failure following stereotactic body radiation therapy in early stage non-small-cell lung cancer: clinical implications. Radiother Oncol 2010;94:1-11. doi: 10.1016/j. radonc.2009.12.008
29. Brown JM, Diehn M, Loo BW Jr. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 2010;78:323-7. doi: 10.1016/j.ijrobp.2010.04.070
30. Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S. Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011;6:1221-8. doi: 10.1097/JTO.0b013e318219aac5
31. Senan S, Huang K, Senthi S, Spoelstra F, Warner A, Slotman BJ, et al. Blinded assessment of radiological changes after stereotactic ablative radiotherapy (SABR) for early-stage lung cancer: local recurrences versus fibrosis. J Clin Oncol 2013;31:suppl; abstr 7520.